216 related articles for article (PubMed ID: 8680005)
1. [Effects of potentiation and rapid action in models of venous thrombosis in dogs upon combined administration of the plasminogen tissue activator and urokinase modified by fibrinogen].
Maksimenko AV; Tishchenko EG; Petrova ML; Golubykh VL
Biull Eksp Biol Med; 1996 Jan; 121(1):48-51. PubMed ID: 8680005
[No Abstract] [Full Text] [Related]
2. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
Collen D
Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
[No Abstract] [Full Text] [Related]
3. [Combined thrombolysis by pharmacokinetically different plasminogen activators].
Maksimenko AV
Bioorg Khim; 1998 May; 24(5):376-80. PubMed ID: 9661792
[TBL] [Abstract][Full Text] [Related]
4. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.
Stassen JM; Juhan-Vague I; Alessi MC; De Cock F; Collen D
Thromb Haemost; 1987 Oct; 58(3):947-50. PubMed ID: 2829381
[TBL] [Abstract][Full Text] [Related]
5. Thrombolytic effect after sequential double-bolus administration of tissue plasminogen activator and urokinase-fibrinogen conjugate into dogs with venous thrombosis.
Maksimenko AV; Tischenko EG; Golubykh VL
Ann N Y Acad Sci; 1998 Dec; 864():409-17. PubMed ID: 9928118
[No Abstract] [Full Text] [Related]
6. Alteplase as an alternative to urokinase. Advisory Panel on Catheter-Directed Thrombolytic Therapy.
Semba CP; Bakal CW; Calis KA; Grubbs GE; Hunter DW; Matalon TA; Murphy TP; Stump DC; Thomas S; Warner DL
J Vasc Interv Radiol; 2000 Mar; 11(3):279-87. PubMed ID: 10735420
[No Abstract] [Full Text] [Related]
7. [Thrombolytic efficacy of a Lys-plasminogen-urokinase combination: studies in experimental animals and humans].
Latorre J; Foncuberta J; Rosendo A; Elez J
Angiologia; 1990; 42(6):218-26. PubMed ID: 2075946
[TBL] [Abstract][Full Text] [Related]
8. Use of urokinase in pregnancy. Two success stories.
La Valleur J; Molina E; Williams PP; Rolnick SJ
Postgrad Med; 1996 May; 99(5):269-70, 272-3. PubMed ID: 8650092
[TBL] [Abstract][Full Text] [Related]
9. Criteria for use of regional urokinase infusion for deep vein thrombosis.
Kaul AF; Tomera JF
Am J Health Syst Pharm; 1997 Sep; 54(17):2002-3. PubMed ID: 9290901
[No Abstract] [Full Text] [Related]
10. [Cerebral infarction--thrombolytic therapy by tissue-type plasminogen activator or prourokinase].
Amano T
Nihon Rinsho; 1989 Apr; 47(4):917-20. PubMed ID: 2501542
[No Abstract] [Full Text] [Related]
11. Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase.
Gurewich V
Semin Thromb Hemost; 1989 Apr; 15(2):123-8. PubMed ID: 2501871
[No Abstract] [Full Text] [Related]
12. The development of thrombolytic treatment in venous thrombosis. Experience with streptokinase-based regimens.
Marbet GA; Duckert F
Vasa; 1986; 15(4):359-64. PubMed ID: 3799023
[No Abstract] [Full Text] [Related]
13. Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents.
Collen D; Stump DC; Van de Werf F
Am Heart J; 1986 Nov; 112(5):1083-4. PubMed ID: 3096127
[No Abstract] [Full Text] [Related]
14. Venous thrombolysis by tissue-type plasminogen activator in conjunction with the urokinase-fibrinogen covalent conjugate. Effects of potentiation and faster action in dogs.
Maksimenko AV; Tischenko EG; Petrov AD; Petrova ML; Golubykh VL
Appl Biochem Biotechnol; 1996; 61(1-2):123-8. PubMed ID: 9100350
[TBL] [Abstract][Full Text] [Related]
15. [Coronary thrombolysis by t-PA and pro-UK].
Kanmatsuse K; Suzuki T; Kajiwara N
Nihon Rinsho; 1989 Apr; 47(4):910-6. PubMed ID: 2501541
[No Abstract] [Full Text] [Related]
16. Fibrinolysis with intrathrombic injection of urokinase and tissue-type plasminogen activator. Results in a new model of subacute venous thrombosis.
Valji K; Bookstein JJ
Invest Radiol; 1987 Jan; 22(1):23-7. PubMed ID: 3102398
[TBL] [Abstract][Full Text] [Related]
17. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
Paloma MJ; Páramo JA; Rocha E
Thromb Haemost; 1995 Dec; 74(6):1578-82. PubMed ID: 8772240
[TBL] [Abstract][Full Text] [Related]
18. Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator.
Gurewich V
J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):16B-21B. PubMed ID: 3117859
[TBL] [Abstract][Full Text] [Related]
19. [Fibrinolytic therapy of acute venous thrombosis].
Theiss W
Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir; 1990; ():443-8. PubMed ID: 1983587
[TBL] [Abstract][Full Text] [Related]
20. Potentiation by heparin fragment CY 222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator.
Juhan-Vague I; Stassen JM; Alessi MC; Elias A; Aillaud MF; Serradimigni A; Collen D
Semin Thromb Hemost; 1989 Oct; 15(4):390-4. PubMed ID: 2554499
[No Abstract] [Full Text] [Related]
[Next] [New Search]
